A 66-year-old woman with rheumatoid arthritis, osteoporosis, gastro-oesophageal reflux disease, and hypertension attends for routine review. Her medications include methotrexate 15mg weekly, folic acid 5mg weekly, alendronic acid 70mg weekly, omeprazole 20mg OD, amlodipine 10mg OD, and she takes over-the-counter ibuprofen 400mg TDS for joint pain. Recent blood tests show Hb 98 g/L (normal 115-165), MCV 76 fL (normal 80-100), and eGFR 52 mL/min/1.73m² (previously 68). What is the most important prescribing issue to address?
Q162
A 70-year-old man with heart failure, atrial fibrillation, hypertension, gout, and depression is taking multiple medications. During a medication review, you identify that he is taking warfarin, furosemide 80mg BD, ramipril 10mg OD, bisoprolol 10mg OD, allopurinol 300mg OD, and sertraline 100mg OD. His INR has been unstable over the past 3 months, ranging from 1.8 to 4.2 despite good reported compliance. Which of the following is the most appropriate strategy to address his unstable anticoagulation?
Q163
A 74-year-old woman with dementia, Parkinson's disease, type 2 diabetes, and recurrent urinary tract infections attends with her daughter. Her medications include co-careldopa 25/100mg TDS, donepezil 10mg OD, metformin 500mg BD, and she was recently prescribed prophylactic trimethoprim 100mg nocte by a locum GP for recurrent UTIs. The daughter reports that her mother has become increasingly confused and agitated over the past week, with worsening tremor and rigidity. What is the most likely medication-related cause of her deterioration?
Q164
A 68-year-old man with ischaemic heart disease, type 2 diabetes, hypertension, and hyperlipidaemia presents for his annual review. He takes aspirin 75mg OD, clopidogrel 75mg OD, bisoprolol 2.5mg OD, ramipril 10mg OD, atorvastatin 80mg OD, metformin 1g BD, and gliclazide 80mg BD. He had a drug-eluting stent inserted 18 months ago. He has no angina symptoms. His HbA1c is 64 mmol/mol and blood pressure is 128/76 mmHg. What is the most appropriate change to his antiplatelet therapy?
Q165
During a structured medication review, you are assessing a 72-year-old woman taking 12 different medications for multiple conditions. According to current UK guidance on medication reviews in primary care, which framework is recommended for conducting a comprehensive structured medication review to optimize prescribing and reduce polypharmacy-related harm?
Q166
A 65-year-old man with heart failure (NYHA class II), atrial fibrillation, and chronic obstructive pulmonary disease attends for annual review. His medications include bisoprolol 5mg OD, ramipril 5mg BD, furosemide 40mg OD, spironolactone 25mg OD, apixaban 5mg BD, tiotropium inhaler, and salbutamol inhaler PRN. He reports feeling generally well but has noticed increased breathlessness on exertion over the past 3 months. Examination reveals bilateral basal crackles and mild peripheral oedema. Which aspect of his multimorbidity management requires the most urgent review?
Q167
A 78-year-old woman with type 2 diabetes, hypertension, chronic kidney disease stage 3a, and osteoarthritis attends for a medication review. Her current medications include metformin 500mg BD, ramipril 10mg OD, amlodipine 5mg OD, atorvastatin 20mg OD, aspirin 75mg OD, paracetamol 1g QDS, and codeine 30mg QDS. Her eGFR has declined from 52 to 38 mL/min/1.73m² over the past year. Blood pressure is 142/84 mmHg. HbA1c is 58 mmol/mol. What is the most appropriate immediate medication change?
Chronic Disease Management UK Medical PG Practice Questions and MCQs
Question 161: A 66-year-old woman with rheumatoid arthritis, osteoporosis, gastro-oesophageal reflux disease, and hypertension attends for routine review. Her medications include methotrexate 15mg weekly, folic acid 5mg weekly, alendronic acid 70mg weekly, omeprazole 20mg OD, amlodipine 10mg OD, and she takes over-the-counter ibuprofen 400mg TDS for joint pain. Recent blood tests show Hb 98 g/L (normal 115-165), MCV 76 fL (normal 80-100), and eGFR 52 mL/min/1.73m² (previously 68). What is the most important prescribing issue to address?
A. The ibuprofen use is causing renal impairment and should be stopped (Correct Answer)
B. Omeprazole is causing iron deficiency anaemia and should be stopped
C. Alendronic acid should be stopped due to renal impairment
D. Folic acid timing needs adjusting to avoid interaction with methotrexate
E. Methotrexate dose should be reduced due to declining renal function
Explanation: ***The ibuprofen use is causing renal impairment and should be stopped***
- Regular **NSAID** use like **ibuprofen** is the most critical issue because it explains both the **declining eGFR** (via renal vasoconstriction) and the **microcytic anaemia** (via chronic gastrointestinal blood loss).
- Additionally, combining **NSAIDs** with **methotrexate** is high-risk as it can reduce renal excretion of methotrexate, leading to potential **toxicity**.
*Omeprazole is causing iron deficiency anaemia and should be stopped*
- While **PPIs** like **omeprazole** can theoretically hinder iron absorption by increasing gastric pH, they are protective against **NSAID-induced gastropathy**.
- In this patient, the **microcytic anaemia** is far more likely caused by **NSAID-induced GI bleeding** than by PPI-mediated malabsorption.
*Alendronic acid should be stopped due to renal impairment*
- **Alendronic acid** is generally considered safe to continue until the **eGFR** drops below **35 mL/min/1.73m²**.
- With a current eGFR of **52 mL/min/1.73m²**, there is no immediate contraindication to its use based on renal function alone.
*Folic acid timing needs adjusting to avoid interaction with methotrexate*
- **Folic acid** is correctly prescribed to be taken weekly (usually at least 24 hours after the methotrexate dose) to mitigate **methotrexate side effects**.
- While scheduling is important, it is a minor management detail compared to the active **renal damage** and **anaemia** caused by ibuprofen.
*Methotrexate dose should be reduced due to declining renal function*
- While **methotrexate dose** monitoring is necessary as renal function declines, the current **eGFR of 52** does not typically necessitate an immediate dose reduction.
- The priority is to address the **nephrotoxic agent** (ibuprofen) first to see if renal function stabilizes before altering essential **RA treatment**.
Question 162: A 70-year-old man with heart failure, atrial fibrillation, hypertension, gout, and depression is taking multiple medications. During a medication review, you identify that he is taking warfarin, furosemide 80mg BD, ramipril 10mg OD, bisoprolol 10mg OD, allopurinol 300mg OD, and sertraline 100mg OD. His INR has been unstable over the past 3 months, ranging from 1.8 to 4.2 despite good reported compliance. Which of the following is the most appropriate strategy to address his unstable anticoagulation?
A. Increase frequency of INR monitoring to weekly
B. Switch from warfarin to a direct oral anticoagulant (DOAC) (Correct Answer)
C. Reduce sertraline dose as SSRIs increase INR
D. Add vitamin K supplementation to stabilize INR
E. Stop allopurinol as it interferes with warfarin metabolism
Explanation: ***Switch from warfarin to a direct oral anticoagulant (DOAC)***
- **DOACs** provide more predictable pharmacokinetics and have significantly fewer **drug-drug and drug-food interactions** than warfarin, making them ideal for complex patients with polypharmacy.
- National guidelines (such as NICE) suggest switching to a **DOAC** if time in therapeutic range (TTR) is low or if there is **unstable INR** control despite compliance.
*Increase frequency of INR monitoring to weekly*
- Increased monitoring may identify deviations but fails to address the underlying physiological or pharmacological causes of **INR instability**.
- This approach increases the **treatment burden** for the elderly patient without providing the superior stroke protection associated with stable anticoagulation.
*Reduce sertraline dose as SSRIs increase INR*
- While **SSRIs** like sertraline can increase bleeding risk by affecting **platelet function**, reducing the dose may destabilize the patient's **depression** management.
- Adjusting the antidepressant dose does not solve the fundamental issue of warfarin's narrow **therapeutic index** in a polypharmacy context.
*Add vitamin K supplementation to stabilize INR*
- Regular low-dose **Vitamin K** is sometimes used for extreme instability, but it is complex to manage and can lead to **warfarin resistance**.
- It is not a first-line strategy when a more reliable alternative like a **DOAC** is available and indicated for AF.
*Stop allopurinol as it interferes with warfarin metabolism*
- Stopping **allopurinol** unnecessarily risks a flare of **gout**, especially in a patient already taking a diuretic like furosemide.
- While some interactions exist, removing essential chronic disease medications is inferior to switching to an anticoagulant that does not require **metabolic monitoring**.
Question 163: A 74-year-old woman with dementia, Parkinson's disease, type 2 diabetes, and recurrent urinary tract infections attends with her daughter. Her medications include co-careldopa 25/100mg TDS, donepezil 10mg OD, metformin 500mg BD, and she was recently prescribed prophylactic trimethoprim 100mg nocte by a locum GP for recurrent UTIs. The daughter reports that her mother has become increasingly confused and agitated over the past week, with worsening tremor and rigidity. What is the most likely medication-related cause of her deterioration?
A. Drug interaction between trimethoprim and metformin causing lactic acidosis
B. Trimethoprim-induced folate deficiency affecting neurological function (Correct Answer)
C. Donepezil toxicity due to accumulation
D. Drug interaction between trimethoprim and donepezil causing serotonin syndrome
E. Inadequate Parkinson's disease control requiring dose increase
Explanation: ***Trimethoprim-induced folate deficiency affecting neurological function***
- **Trimethoprim** is a **folate antagonist** that inhibits dihydrofolate reductase; even low-dose prophylactic use can lead to **folate deficiency**, particularly in elderly patients with pre-existing comorbidities and potential nutritional deficiencies.
- **Folate deficiency** can manifest as neuropsychiatric symptoms like **confusion** and **agitation**, and can exacerbate existing neurological conditions such as **Parkinson's disease**, leading to worsening tremor and rigidity.
*Drug interaction between trimethoprim and metformin causing lactic acidosis*
- While **trimethoprim** can inhibit renal tubular secretion of **metformin**, increasing its plasma concentration, clinically significant **lactic acidosis** due to this interaction is rare without profound renal impairment.
- **Lactic acidosis** typically presents with systemic symptoms like metabolic acidosis, tachypnea, and severe gastrointestinal upset, which are not the primary features described here.
*Donepezil toxicity due to accumulation*
- **Donepezil** is primarily metabolized by hepatic CYP enzymes, and there is no significant interaction with **trimethoprim** known to cause rapid accumulation or toxicity in this specific manner.
- **Donepezil toxicity** (cholinergic crisis) would typically present with symptoms such as bradycardia, excessive salivation, miosis, diarrhea, and muscle weakness, rather than primarily increased rigidity and tremor.
*Drug interaction between trimethoprim and donepezil causing serotonin syndrome*
- Neither **trimethoprim** nor **donepezil** are potent serotonergic agents, and there is no established drug interaction between them that would lead to **serotonin syndrome**.
- **Serotonin syndrome** is characterized by a distinct triad of cognitive, autonomic, and neuromuscular symptoms (e.g., hyperreflexia, clonus), which does not fully align with the described worsening of Parkinsonian rigidity and tremor.
*Inadequate Parkinson's disease control requiring dose increase*
- The acute onset of **confusion** and **agitation** alongside worsening motor symptoms, specifically following the introduction of a new medication (**trimethoprim**), strongly suggests a drug-induced cause rather than a sudden natural progression of **Parkinson's disease**.
- While symptoms are worsening, the rapid and acute nature of the deterioration with neuropsychiatric features points towards an adverse drug reaction or interaction.
Question 164: A 68-year-old man with ischaemic heart disease, type 2 diabetes, hypertension, and hyperlipidaemia presents for his annual review. He takes aspirin 75mg OD, clopidogrel 75mg OD, bisoprolol 2.5mg OD, ramipril 10mg OD, atorvastatin 80mg OD, metformin 1g BD, and gliclazide 80mg BD. He had a drug-eluting stent inserted 18 months ago. He has no angina symptoms. His HbA1c is 64 mmol/mol and blood pressure is 128/76 mmHg. What is the most appropriate change to his antiplatelet therapy?
A. Continue both aspirin and clopidogrel indefinitely due to diabetes
B. Stop clopidogrel and continue aspirin alone (Correct Answer)
C. Stop aspirin and continue clopidogrel alone
D. Stop both antiplatelet agents and commence rivaroxaban
E. Continue both agents for a further 6 months then review
Explanation: ***Stop clopidogrel and continue aspirin alone***- After **drug-eluting stent (DES)** insertion, **dual antiplatelet therapy (DAPT)** with aspirin and clopidogrel is typically given for **12 months** to prevent **stent thrombosis**.- Given the patient is **18 months post-stent** and stable, **aspirin monotherapy** is the recommended long-term strategy for secondary cardiovascular prevention.*Continue both aspirin and clopidogrel indefinitely due to diabetes*- While **diabetes** is a risk factor, continuing **DAPT indefinitely** beyond 12 months for stable patients significantly increases the **risk of major bleeding** without clear additional benefit.- Current guidelines recommend transitioning to **antiplatelet monotherapy** after the initial DAPT period in patients with DES who are stable.*Stop aspirin and continue clopidogrel alone*- **Aspirin** is generally the preferred agent for **lifelong antiplatelet monotherapy** in secondary prevention of ischaemic heart disease due to its proven efficacy and cost-effectiveness.- **Clopidogrel monotherapy** is typically reserved for patients with a **contraindication or intolerance to aspirin**, which is not indicated in this patient's presentation.*Stop both antiplatelet agents and commence rivaroxaban*- **Rivaroxaban** is an anticoagulant, not an antiplatelet, and is generally used for conditions like **atrial fibrillation** or VTE prophylaxis, or in combination with aspirin in specific high-risk IHD patients (e.g., COMPASS trial).- Discontinuing all antiplatelet therapy in a patient with **ischaemic heart disease** and a **history of stent insertion** would expose him to a high risk of recurrent thrombotic events.*Continue both agents for a further 6 months then review*- The patient is already **18 months post-stent**, exceeding the standard **12-month DAPT duration** for DES.- Prolonging DAPT beyond the recommended period in stable patients increases the **bleeding risk** without a demonstrated reduction in ischaemic events.
Question 165: During a structured medication review, you are assessing a 72-year-old woman taking 12 different medications for multiple conditions. According to current UK guidance on medication reviews in primary care, which framework is recommended for conducting a comprehensive structured medication review to optimize prescribing and reduce polypharmacy-related harm?
A. The STOPP/START criteria (Correct Answer)
B. The Beers criteria
C. The Medication Appropriateness Index (MAI)
D. The Prescribing Observatory for Mental Health (POMH-UK) standards
E. The NICE Medicines Optimisation guidelines
Explanation: ***The STOPP/START criteria***- The **STOPP/START** (Screening Tool of Older Persons' Prescriptions/Screening Tool to Alert to Right Treatment) criteria are the evidence-based framework recommended in the **UK** for conducting clinical medication reviews in older patients.- It helps clinicians identify **Potentially Inappropriate Prescribing (PIP)** and potential omissions of beneficial drugs, effectively managing **polypharmacy** and reducing adverse drug reactions.*The Beers criteria*- The **Beers criteria** is a similar tool used to identify inappropriate medications in the elderly but is primarily used and developed in the **United States**.- While useful, it lacks the 'START' component for identifying omitted medications and is not the standard clinical framework cited in **UK primary care** guidance.*The Medication Appropriateness Index (MAI)*- The **MAI** is a scoring tool used to assess the appropriateness of individual prescriptions based on ten specific criteria such as efficacy and cost.- It is generally considered a **research tool** rather than a practical framework for performing a quick and systematic structured medication review in a busy **Primary Care** setting.*The Prescribing Observatory for Mental Health (POMH-UK) standards*- These standards are specifically designed for the audit and improvement of prescribing within **specialist mental health** services.- They do not provide a comprehensive framework for general **polypharmacy** or the multi-system comorbidities typically seen in structured medication reviews for elderly patients.*The NICE Medicines Optimisation guidelines*- **NICE guidelines** (NG5) provide overarching principles and professional standards for medicines management but do not offer a granular, drug-specific tool like **STOPP/START**.- While they mandate that reviews should be structured, they recommend using specific tools like **STOPP/START** to operationalize the clinical assessment of medication sets.
Question 166: A 65-year-old man with heart failure (NYHA class II), atrial fibrillation, and chronic obstructive pulmonary disease attends for annual review. His medications include bisoprolol 5mg OD, ramipril 5mg BD, furosemide 40mg OD, spironolactone 25mg OD, apixaban 5mg BD, tiotropium inhaler, and salbutamol inhaler PRN. He reports feeling generally well but has noticed increased breathlessness on exertion over the past 3 months. Examination reveals bilateral basal crackles and mild peripheral oedema. Which aspect of his multimorbidity management requires the most urgent review?
A. Increasing bisoprolol dose may worsen his COPD symptoms
B. The beta-blocker may be masking deteriorating heart failure (Correct Answer)
C. Spironolactone should be stopped due to his COPD
D. Apixaban dose may need adjustment for heart failure
E. Tiotropium is contraindicated in patients with atrial fibrillation
Explanation: ***The beta-blocker may be masking deteriorating heart failure***
- The patient's increased breathlessness, **bilateral basal crackles**, and **peripheral oedema** are clear signs of worsening **heart failure** and **fluid overload**.
- **Beta-blockers** like bisoprolol suppress the heart's natural **compensatory tachycardia** in response to falling cardiac output, making it difficult to assess the severity of heart failure based on heart rate alone, thus masking the deterioration.
*Increasing bisoprolol dose may worsen his COPD symptoms*
- **Cardioselective beta-blockers** (like bisoprolol) are generally safe and beneficial in patients with **stable COPD** and are crucial for mortality reduction in **heart failure**.
- While very high doses could theoretically exacerbate bronchospasm, the most urgent issue is the overt signs of **congestive heart failure**, not a hypothetical risk from a dose increase.
*Spironolactone should be stopped due to his COPD*
- **Spironolactone**, a **mineralocorticoid receptor antagonist (MRA)**, is a foundational therapy for **heart failure with reduced ejection fraction (HFrEF)** and is not contraindicated in **COPD**.
- It helps manage **fluid retention** and improves outcomes in heart failure; stopping it would likely worsen his current symptoms of fluid overload.
*Apixaban dose may need adjustment for heart failure*
- **Apixaban** dosing is primarily determined by **renal function** (creatinine clearance), age, and body weight, not directly by the severity of **heart failure** or NYHA class.
- While severe heart failure can affect renal function, there is no direct rule to adjust anticoagulation based solely on breathlessness or oedema without specific renal parameters.
*Tiotropium is contraindicated in patients with atrial fibrillation*
- **Tiotropium**, a **long-acting muscarinic antagonist (LAMA)**, is a standard treatment for **COPD** and is generally not contraindicated in **atrial fibrillation**.
- While anticholinergics should be used with caution if arrhythmias are uncontrolled, the urgent priority here is the management of acute **fluid overload** from heart failure, not the LAMA.
Question 167: A 78-year-old woman with type 2 diabetes, hypertension, chronic kidney disease stage 3a, and osteoarthritis attends for a medication review. Her current medications include metformin 500mg BD, ramipril 10mg OD, amlodipine 5mg OD, atorvastatin 20mg OD, aspirin 75mg OD, paracetamol 1g QDS, and codeine 30mg QDS. Her eGFR has declined from 52 to 38 mL/min/1.73m² over the past year. Blood pressure is 142/84 mmHg. HbA1c is 58 mmol/mol. What is the most appropriate immediate medication change?
A. Stop metformin and commence gliclazide (Correct Answer)
B. Stop codeine and commence a selective COX-2 inhibitor
C. Stop aspirin due to increased bleeding risk with declining renal function
D. Increase ramipril to 15mg OD to improve renal protection
E. Stop amlodipine and increase ramipril dose
Explanation: ***Stop metformin and commence gliclazide***- **Metformin** is contraindicated with an eGFR generally below 30 mL/min/1.73m², but a significant decline to **38 mL/min/1.73m²** in a 78-year-old warrants immediate review due to increased risk of **lactic acidosis**.- **Gliclazide** is primarily metabolized by the liver, making it a safer and appropriate oral hypoglycemic alternative in patients with **moderate renal impairment** (CKD stage 3b) where metformin is a concern.*Stop codeine and commence a selective COX-2 inhibitor*- **Selective COX-2 inhibitors** (NSAIDs) can cause **acute kidney injury** by reducing renal blood flow and are generally contraindicated or used with extreme caution in patients with **chronic kidney disease**.- While **codeine** metabolites can accumulate, replacing it with an **NSAID** would pose a higher and more immediate risk of worsening renal function.*Stop aspirin due to increased bleeding risk with declining renal function*- **Low-dose aspirin (75mg)** is critical for **secondary cardiovascular prevention** in patients with multiple risk factors like diabetes, hypertension, and advanced age.- An eGFR of **38 mL/min/1.73m²** alone does not typically necessitate stopping low-dose aspirin, as the cardiovascular benefits generally outweigh the theoretical bleeding risk in this context.*Increase ramipril to 15mg OD to improve renal protection*- The maximum recommended and licensed dose for **ramipril** is typically **10mg OD**; a 15mg dose is not standard and exceeding the maximum increases adverse effects.- Increasing an **ACE inhibitor** dose in a patient with rapidly declining eGFR can precipitate **hyperkalemia** or further acute kidney injury and should be done with extreme caution and monitoring, not as an immediate change.*Stop amlodipine and increase ramipril dose*- **Ramipril** is already at its **maximum therapeutic dose of 10mg**, so increasing it further is not a clinically viable option.- **Amlodipine** is a safe and effective **antihypertensive** in chronic kidney disease and contributes to blood pressure control without adverse renal effects, so stopping it is not indicated.
